StockData
Prime Medicine, Inc. logo

Prime Medicine, Inc. (PRME) stock

PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.84+0.02 (+0.52%)

Close on Nov 19, 2026Market cap $696.49MP/E –Yield –

Prime Medicine free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Prime Medicine's free cash flow for the twelve months ending Jun 30, 2026 was -$156.85M. For fiscal 2025 it was -$167.10M. The highest annual figure on record is -$6.18M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$167.10M–
FY2024Dec 31, 2024-$130.16M–
FY2023Dec 31, 2023-$174.14M–
FY2022Dec 31, 2022-$147.92M–
FY2021Dec 31, 2021-$38.23M–
FY2020Dec 31, 2020-$6.18M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$41.09M–
Q1 FY2026Mar 31, 2026-$42.92M–
Q4 FY2025Dec 31, 2025-$37.55M-359.8%
Q3 FY2025Sep 30, 2025-$35.29M–
Q2 FY2025Jun 30, 2025-$42.98M–
Q1 FY2025Mar 31, 2025-$51.28M–
Q4 FY2024Dec 31, 2024$14.45M–
Q3 FY2024Sep 30, 2024-$27.19M–
Q2 FY2024Jun 30, 2024-$47.39M–
Q1 FY2024Mar 31, 2024-$70.03M–
Q4 FY2023Dec 31, 2023-$45.70M–
Q3 FY2023Sep 30, 2023-$42.08M–
Q2 FY2023Jun 30, 2023-$42.80M–
Q1 FY2023Mar 31, 2023-$43.56M–
Q4 FY2022Dec 31, 2022-$35.53M–
Q3 FY2022Sep 30, 2022-$34.89M–
Q2 FY2022Jun 30, 2022-$25.03M–
Q1 FY2022Mar 31, 2022-$52.48M–
Q4 FY2021Dec 31, 2021-$13.57M–

More Prime Medicine figures

See a number that looks wrong?